EXEL (Exelixis Inc) Earnings per share for the last four quarters

Under the leadership of Michael Morrissey, Exelixis, Inc. (EXEL) has evolved into an efficient financial machine, successfully monetizing its oncology developments. Historical EPS YoY TTM dynamics demonstrate current earnings, with the metric recorded at 40.20. The company is actively investing in the discovery of new molecules for targeted therapy, seeking to mitigate the risks of key patent expirations by expanding its R&D portfolio.
Exelixis Inc - analytical breakdowns and key metrics (EXEL)

For Exelixis, Inc. (EXEL), earnings per share dynamics reflect the monetization efficiency of its patent-protected oncology portfolio. This metric compares total net income over the last 12 months with the same period last year, measuring the rate of capital expansion. By analyzing the annual growth trend of TTM net income per share, an investor can discern the actual speed of business scaling. The monopoly status of the drugs ensures the stability of this indicator.